Crescita Secures Exclusive Manufacturing Deal in Healthcare
Company Announcements

Crescita Secures Exclusive Manufacturing Deal in Healthcare

Story Highlights
  • Crescita Therapeutics to supply sanitation products under a five-year exclusive agreement.
  • Potential annual revenues could reach $6 million, with opportunities for future growth.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Crescita Therpeutc (TSE:CTX) has released an update.

Crescita Therapeutics Inc., a Canadian dermatology company, has been chosen as the exclusive manufacturing partner in a five-year agreement with a major healthcare services provider to supply skin sanitation products for public healthcare organizations. The deal could potentially generate annual revenue of up to $6 million by the end of the term, with future revenue opportunities through competitive bidding processes and potential expansions in collaborations.

For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskCrescita Therapeutics Positions for Growth Amid Q2 Challenges
TipRanks Canadian Auto-Generated NewsdeskCrescita Therapeutics Secures Lucrative Manufacturing Deal
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App